»

[elmo3]

hey everyone
i know none of us who held enjoyed the ride down as much as we did up
congrats to the ones who sold out at peak and bought back again.

this is my take
figures are not correct but it's the just to show you to what happened today

about 2 weeks ago this stock was under a dollar with a approval date may25 coming lets say shorts had options at $3.00-$4.00 with hope of it not being approved.
look at what this stock traded in last 4 days 140 million shares
total shares 232.40 million
-30 million from the big boys who bought on dilution leaves us with 200 million to play with lets say 20% is longs so leaves us with 180 million shares left 140 million shares changed hand in last four days so that means 40 million shares left now lets say 20 million for heb employees so 20 million for shorts
now if they bought the stock to short at $3.00 that means $ 60 million dollars thinking this is not going to be approved now all of a sudden this bull is bursting through $4.00 like nothing and more & more people getting involved soon as it hits $5.00 the big boys come in to play shorters start to lose big time . so what do you do sell 20 million shares at lower prices trigger off stop losses and scare ppl all of a sudden they covered their shorts with a tiny profit.
They gambled and won 20 million shares worst case scenerio $20 million loss
but if this went to 5 like it was suppose to do today. thats 40 million plus still waiting for approval and you have 1-2 days more to go till approval so do the math lets say by approval it went up another $1.00 not at the pace it was going at thats 60 million .
so in short only people that lost out were the ones who had there stop losses triggered. But this baby gonna make money in long run hey it even saved the shorters butts today...
so watch out monday theres no holding back till approval

look at the volume after this whole drop it picked up just think ppl are that confident in this and realized someting fishy and got back in unlike adls where you couldnt even give it up for free
it had nothing to do with baldy(A.F) or anyone just the shorts

Go Heb Go!

Tony

[croat76]

Originally Posted by AKrider What is your monday premarket prediction?

Approved.

[Hotchkiss1987]

Originally Posted by Adam I've done some research and found that it looks like one dose will cost a lousy $2-3 and two doses would be required!

Ummm... nope. That's not how drugs are priced. I'd have to find the page again in my economics textbook, but basically you divide R&D costs by the amount you're making, and since Ampligen is 30 years in the making, those are some **huge** R&D costs. If the WHO wants the vaccine to be cheap, they might make up the difference, or get a cheaper deal through mass production. I don't think HEB has the capacity to produce 20,000,000+ doses in a very short period of time, (keep in mind I don't actually know this) but that means other companies will be producing the drug too if it works as a vaccine. More companies that aren't competing against each other = higher price than making it all @ HEB.

[Hotchkiss1987]

Just think: if it costs $500,000,000 for R&D, and you want to make 500,000 doses for everyone with CFS, that's $1,000 a dose before you even add in the costs you need to make it (like equipment, salaries, etc, etc)

[vijayakumark]

See this how Timothy Sykes shorted DNDN just 2 days before DNDN approval and all the people who followed his alert lost $20 per share.

How I Just Traded Dendreon Corp. (DNDN) | TIM - Timothy Sykes

[BombTek]

Originally Posted by Pashka This article was posted earlier but Japan might allocate seed money by June 10th - "The National Institute of Infectious Diseases will probably be able to give makers the seed of a vaccine around June 10," Masuzoe told reporters when asked about the newspaper report. Reuters AlertNet - Japan to produce new flu vaccine this year - media

I hear you; but where in that article does it say the word Ampligen or Hemispherx? My point is that while we wish we hear some great news indicating sales come out of the conference, we've been speculating for weeks that Japan was going to be ordering Ampligen and we've yet to hear definitive news. All I'm saying is that we should keep our expectations realistic. If we have yet to see any news regarding commitment from Japan and we've been hearing that news for weeks; then why should we expect to hear something from other countries within 2 days?

I've seen that article as well as another new one from biomedreports that refers to that article. This all good new and appears we may hear something soon.

If we build our expectations up high, and then we keep waiting and waiting for that news to come; then after a while we start to lose faith. If we keep those expecations real, then things follow right on track and our spirit remains intact.

[BombTek]

Originally Posted by Pashka This article was posted earlier but Japan might allocate seed money by June 10th - "The National Institute of Infectious Diseases will probably be able to give makers the seed of a vaccine around June 10," Masuzoe told reporters when asked about the newspaper report. Reuters AlertNet - Japan to produce new flu vaccine this year - media

Originally Posted by Adam Gypsy...I think $130 per dose could be wishful thinking That must be a five-star local clinic you have there... I've done some research and found that it looks like one dose will cost a lousy $2-3 and two doses would be required! Glaxo SmithKline forecast the H1N1 vaccine would be priced in rich countries at about the same level as the conventional seasonal flu shot, at around Ł5 ($7.75) per dose. And according to this website the Pan American Health Organisation say that it would cost a measly $2-3...and that's for the whole vaccine. I wouldn't want to imagine what cut the adjuvant would get! Apparently if you go to France it'll cost $8 The link above has some really good discussion on H1N1 if interested.

While I applaud that you were the first to present any good data on the cost of vaccines, you have to remember that Ampligen works as a mucosal vaccine. Meaning that it needs to enter the mucose membanes, because this is where it is more effective. The vaccines referred to here are injections. This has been determined to not be as effective. However, we don't know if there will be a difference with the average cost you provided. We should remember though that Ampligen is extremely expensive to manufacture. On the other hand, only a very small amount is required when used as an adjuvant.

[BombTek]

This is a new article that I believe was somehow overlooked yesterday:

HEMISPHERX (HEB) AND ANTIGENICS (AGEN): INDISPENSABLE VACCINE ADJUVANTS

VACCINE ADJUVANTS: INDISPENSABLE FOR VACCINES

Metasearch Search Engine - Search.com

[GypsyDRB]

Good stuff BombTek!

Adam - thanks for the links! That is good stuff to know. I just wanted to steer the conversation in the direction of getting people to think about post FDA decision...because there could be some buying opportunities if we can try and zero in on a cost / profit for HEB's adjuvants and correlate that to a "floor" or base price of HEB.

If HEB drops on being denied for CFS again down to say 50 cents well then I'm going to back the truck up and load up...but if it only drops to say 1.50 or 1.75...well I may just ride it out.

Can I change my Friday AH prediction to Monday AH?!?!?

[imeanbusiness]

Good morning everyone. I just noticed that BioMedReports has released this new article that makes some justice against AF yesterday's attacks against HEB.
Have a great weekend.

Biggest winners become biggest losers after Friday's action on the Street - BioMedReports.com

Meanwhile, Hemispherx Biopharma's shares started the day on Friday as one of the top gainers, yet it ended up as the sector's biggest loser without any solid piece of bad news. Instead share prices were affected adversely after the company was hit twice the same day with negative opinion pieces from Street.Com's biotech columnist Adam Feuerstein. The powerful Wall Street portal alleges, among other things, that the company's claims that approval is pending for its chronic fatigue syndrome drug are based on an 8-year-old government report and that CEO, Dr. William Carter is desperately trying to pump up its stock price before the FDA rejects Ampligen.
Missed by most HEB investors were two positive developments.

First, Reuters reported that Japan plans to produce enough H1N1 flu vaccine to treat 20 million people by the end of year. The company has been in discussions and testing their flu platforms with that country for quite some time.

“The highest level of the Japanese government and public medical community is now focused exclusively on our product,” Carter told BioMedReports last week. “They stopped working on all other adjuvants (boosters) and are only working with this one because they’ve found that it enhances the vaccines by 100 fold.”

Second, Prohost Biotechnology, an independent publication which evaluates biotechnology companies, their products, technologies, scientists and managers, as well as their finances for fund managers, investors, medical professionals issued a report on Friday calling both Hemispherx's Ampligen and Antigenics’(Nasdaq:AGEN) QS-21 Stimulon the two most indespenable vaccine adjuvants. "We need adjuvants and Ampligen is among those whom we really need to have available to infectious disease and oncology specialists" said the report.

Peer-reviewed medical publications, have reported key findings with a view to offering a rationale for the use of Ampligen as a potentially safe adjuvant- one recently published one from Cardiff Univeristy even summizes that the drug is capable of overcoming tumour-related immune tolerance mechanisms in a clinical setting.